Laurenti, Luca
 Distribuzione geografica
Continente #
NA - Nord America 9.571
EU - Europa 8.519
AS - Asia 3.995
SA - Sud America 427
OC - Oceania 168
AF - Africa 108
Continente sconosciuto - Info sul continente non disponibili 10
Totale 22.798
Nazione #
US - Stati Uniti d'America 9.405
DE - Germania 2.342
SE - Svezia 1.697
SG - Singapore 1.460
CN - Cina 1.453
IT - Italia 1.389
UA - Ucraina 679
IE - Irlanda 532
FR - Francia 472
GB - Regno Unito 406
BR - Brasile 353
IN - India 341
ID - Indonesia 328
RU - Federazione Russa 234
FI - Finlandia 214
AU - Australia 141
CA - Canada 124
TR - Turchia 108
NL - Olanda 97
PL - Polonia 84
HK - Hong Kong 60
AT - Austria 48
BE - Belgio 44
CI - Costa d'Avorio 42
ES - Italia 37
JP - Giappone 37
MX - Messico 31
CH - Svizzera 29
HU - Ungheria 28
CZ - Repubblica Ceca 27
NZ - Nuova Zelanda 27
IR - Iran 26
AR - Argentina 25
RO - Romania 25
KR - Corea 21
EG - Egitto 18
GR - Grecia 16
IL - Israele 16
PT - Portogallo 14
VN - Vietnam 13
ZA - Sudafrica 13
TH - Thailandia 12
CL - Cile 11
LT - Lituania 11
MA - Marocco 11
SA - Arabia Saudita 11
BG - Bulgaria 10
NO - Norvegia 10
BD - Bangladesh 9
CO - Colombia 9
DZ - Algeria 9
IQ - Iraq 9
LK - Sri Lanka 9
PE - Perù 9
SK - Slovacchia (Repubblica Slovacca) 9
HR - Croazia 8
BA - Bosnia-Erzegovina 7
EC - Ecuador 7
PK - Pakistan 7
UZ - Uzbekistan 7
AE - Emirati Arabi Uniti 6
EU - Europa 6
MD - Moldavia 6
MY - Malesia 6
NP - Nepal 6
RS - Serbia 6
SI - Slovenia 6
EE - Estonia 5
KZ - Kazakistan 5
LB - Libano 5
LV - Lettonia 5
VE - Venezuela 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AM - Armenia 4
AZ - Azerbaigian 4
BY - Bielorussia 4
BZ - Belize 4
GE - Georgia 4
KG - Kirghizistan 4
MK - Macedonia 4
PH - Filippine 4
QA - Qatar 4
TW - Taiwan 4
BO - Bolivia 3
JO - Giordania 3
ME - Montenegro 3
UY - Uruguay 3
AL - Albania 2
CM - Camerun 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GA - Gabon 2
GH - Ghana 2
KE - Kenya 2
LI - Liechtenstein 2
LU - Lussemburgo 2
LY - Libia 2
MN - Mongolia 2
Totale 22.780
Città #
Chandler 1.403
Singapore 814
Ashburn 662
Dublin 516
Jacksonville 415
San Mateo 355
Jakarta 316
Dearborn 304
Nanjing 299
Wilmington 269
Milan 246
Beijing 240
Ann Arbor 219
New York 193
Hyderabad 182
Boston 178
Florence 176
Cattolica 170
Los Angeles 148
Woodbridge 145
Moscow 141
Redwood City 140
Houston 138
Lawrence 131
Rome 131
Princeton 127
Seattle 125
Nanchang 121
Nürnberg 121
Redmond 111
Munich 106
Marseille 105
Lancaster 103
Fairfield 96
Izmir 82
Kunming 80
Bremen 79
Frankfurt am Main 71
Chicago 66
Mountain View 56
Boardman 55
Helsinki 54
Shenyang 54
Warsaw 54
Hong Kong 52
Norwalk 49
Washington 45
Tianjin 43
Zhengzhou 43
Abidjan 42
Düsseldorf 41
Brussels 40
London 40
Hebei 38
Hefei 38
Pune 38
Guangzhou 37
Jiaxing 35
Cambridge 34
Hangzhou 34
Changsha 31
Toronto 31
Auburn Hills 30
Sydney 30
Phoenix 28
San Francisco 28
Shanghai 28
Lauterbourg 27
Melbourne 27
Philadelphia 26
Portland 25
Minneapolis 24
Nuremberg 24
São Paulo 24
Vienna 24
The Dalles 23
Adelaide 22
Brisbane 22
Leawood 22
Portsmouth 22
Santa Clara 22
University Park 22
Fremont 21
Busto Arsizio 20
Detroit 20
Paris 20
Augusta 18
Jinan 18
Lanzhou 17
Albany 16
Bologna 16
Brooklyn 16
Changchun 16
Turin 16
Brno 15
Budapest 15
Padova 15
Amsterdam 14
Buffalo 14
San Diego 14
Totale 11.109
Nome #
VITAMIN B12 DEFICIENCY: CORRELATION BETWEEN MTHFR POLYMORPHISMS AND CLINICAL AND LABORATORY FINDINGS 2.595
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 598
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST LINE TREATMENT FOR HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA: AN INTENTION TO TREAT-ANALYSIS 370
Reliability of leukostasis grading score to identify patients with high-risk hyperleukocytosis 317
Factors associated with mortality in bacteremic patients with hematologic malignancies. 309
Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12 288
Factors associated with mortality in bacteremic patients with hematologic malignancies. 176
Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome 157
Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. 156
Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation 154
Prospective study of hepatitis B virus reactivation in patients with hematological malignancies 152
Correlation between paraproteinaemia and viral reactivation after allo-SCT 150
Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma. A pilot study. 145
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. 144
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 143
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 136
Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation 135
Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia 133
Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: Safety and efficacy evaluation. 128
Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia 125
Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab. 125
Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre-transplant therapy 125
Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients 125
All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients 115
New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia 114
EXTREME THROMBOCYTOSIS IN CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS 114
Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication 114
The use of low-dose alemtuzumab in pretreated B-cell chronic lymphocytic leukemia. Leukemia. 112
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration 112
Role of 18F-FDG PET-CT for evaluating the response to reduced-intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: preliminary results in nine patients. 112
Clinical and pathological heterogeneity in a series of 31 patients with IgM-related neuropathy 111
Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia 111
revalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience. 111
Work related acute leukemia and mucor mycosis in a boat-builder 109
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation 109
AB0 type does not affect platelet engraftment after autologous peripheral blood stem cell transplant in a series of 249 hematologic patients 109
Guillain-Barre' syndrome following Varicella zoster reactivation in Chronic Lymphocytic Leukemia treated with fludarabine 108
Hyperleukocytosis and leukostasis: management of a medical emergency 107
Neurologic improvement after peripheral blood stem cell transplantation in poems 106
Role of (18)F-FDG PET-CT for evaluating the response to reduced-intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: preliminary results in nine patients 106
Hyperleukocytosis and leukostasis: management of a medical emergency 106
Light chain deposition in peripheral nerve as a cause of mononeuritis multiplex in Waldenström's macroglobulinaemia. 104
H1N1 Influenza among Hematological Patients: Monocentric Influenza Cases from 2011 to 2016 104
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 104
The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue 103
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome 103
Usefulness of F-18 FDG PET/CT in the follow-up of POEMS syndrome after autologous peripheral blood stem cell transplantation 101
Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience 100
Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience 100
Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma: a pilot study 99
Mycosis fungoides as a cause of severe obstructive sleep apnea 98
Invasive fungal infections in chronic lymphoproliferative disorders: A monocentric retrospective study 98
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 96
TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients 95
Granulocyte transfusions as adjunctive treatment of invasive fungal diseases in neutropenic patients 93
Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units 93
The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia 92
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease 92
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 91
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 90
Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience 90
Long-term follow up of frontline therapy with fludarabine and cyclophosphamide in chronic lymphocytic leukemia: impact of biological parameters on clinical outcome 90
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 90
Non-tunnelled central venous catheters in adult stem cell transplantation recipients: an effective option 89
High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia 88
B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia 87
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia 87
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome 86
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage 85
Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience 84
Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience 84
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 84
Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections. 82
Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia 81
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 81
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid 78
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience 77
Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group 77
Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers 76
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells 75
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 75
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics 75
Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease 74
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia 74
Unrelated cord blood transplantation and post-transplant cyclophosphamide 74
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 74
The Syk kinase as a therapeutic target in leukemia and lymphoma 73
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia 73
Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL 73
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 73
Chronic Lymphocitic Leukaemia: Census of Patients Treated in Italian Haematology Units 72
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. 71
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 71
SARS CoV 2 infection in chronic myelogenous leukemia: Severe hematological presentation 71
High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders 70
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 70
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 69
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study 68
Allogeneic hematopoietic stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult: Monocentric observational study and review of the literature 68
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 68
Totale 13.835
Categoria #
all - tutte 110.421
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.421


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020386 0 0 0 0 0 0 0 0 0 0 213 173
2020/20211.559 60 168 50 144 221 115 146 38 194 65 317 41
2021/20222.259 184 131 131 152 168 65 38 322 107 126 428 407
2022/20234.433 632 628 351 545 332 555 197 308 503 87 215 80
2023/20244.056 126 733 201 777 226 502 196 110 133 234 389 429
2024/20254.264 379 276 507 247 490 206 202 311 833 713 100 0
Totale 23.200